Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: A comparative study

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 485-492

  Gabriel, A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Antipsychotics; Augmentation; Depression; Novels; Treatment

Indexed keywords

CITALOPRAM; OLANZAPINE; QUETIAPINE; RISPERIDONE; VENLAFAXINE;

ADJUVANT THERAPY; ADULT; AGED; AKATHISIA; ARTICLE; BEDTIME DOSAGE; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELUSION; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; FEMALE; GALACTORRHEA; HALLUCINATION; HAND TREMOR; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREMOR; WEIGHT CHANGE; WEIGHT GAIN;

EID: 84876198491     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S42745     Document Type: Article

References (41)

1. Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in general population. Am J psychiatry. 2002; 159(11):1855-1861.
2. Rothschild AJ, Winer J, Flint AJ, et al; Study of Pharmacotherapy of Psychotic Depression (STOP-PD) Collaborative Study Group. Missed diagnosis of psychotic depression at 4 academic medical centers. J Clin Psychiatry. 2008;69(8):1293-1296.
3. Schatzberg AF. New approaches to managing psychotic depression. J Clin Psychiatry. 2003;64 Suppl 1:19-23.
4. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry. 1993;54(9):338-342.
5. Wolfersdorf M, Barg T, König F, Leibfarth M, Grünewald I. Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychiatry. 1995;28(2):56-60.
6. Weizman R, Weizman A. Use of atypical antipsychotics in mood disorders. Curr Opin Investig Drugs. 2001;2(7):940-945.
7. Möller HJ. Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. Eur Arch Psychiatry Clin Neurosci. 2005;255(2):83-93.
8. Leadholm AK, Rothschild AJ, Nolen WA, Bech P, Munk-Jørgensen P, Ostergaard SD. The treatment of psychotic depression: is there consensus among guidelines and psychiatrists? J Affect Disord. 2013;145(2): 214-220.
9. Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry. 2012;12:160.
10. Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2012;27(1):27-39.
11. Katila H, Mezhebovsky I, Mulroy A, et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry. Epub June 7, 2012.
12. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13(7):917-932.
13. Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs. 2012;26(5):435-460.
14. Thase ME, Demyttenaere K, Earley WR, Gustafsson U, Udd M, Eriksson H. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety. 2012;29(7):574-586.
15. Sheehan DV, Locklear J, Svedsäter H, Datto C. Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate. Int Clin Psychopharmacol. 2012;27(5):239-248.
16. Gabriel A. The extended-release formulation of quetiapine fumarate (quetiapine XR) adjunctive treatment in partially responsive generalized anxiety disorder (GAD): an open label naturalistic study. Clin Ter. 2011;162(2):113-118.
17. Sajatovic M, Mullen JA, Sweitzer DF. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry. 2002;63(12):1156-1163.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, DSM-IV. Washington, DC: APA; 1994.
19. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33.
20. National Institute of Mental health. CGI: Clinical global impression. In: Guy W, Bonato RR, editors. Manual for the ECDEU Assessment Battery, 2nd ed. Bethesda, MD: US Department of Health, Education, and Welfare, National Institute of Mental Health; 1970.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
22. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799-812.
23. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry.1998;55(3):250-258.
24. Keck PE Jr, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry. 2000;61 Suppl 3:4-9.
25. Emsley RA, Buckley P, Jones AM, Greenwood MR. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol. 2003;17(2):210-215.
26. Cheer SM, Wagstaff AJ. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs. 2004;18(3):173-199.
27. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry. 1999;156(8):1138-1148.
28. Khouzam HR. Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine. Depress Anxiety. 2000;11(2): 80-82.
29. Babinkostova Z, Stefanovski B. Forms of antipsychotic therapy: improved individual outcomes under personalised treatment of schizophrenia focused on depression. EPMA J. 2011;2(4):391-402.
30. Matthews JD, Bottonari KA, Polania LM, et al. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J Clin Psychiatry. 2002;63(12):1164-1170.
31. Bhana N, Perry CM. Olanzapine: a review of its use in the treatment of bipolar I disorder. CNS Drugs. 2001; 15(11):871-904.
32. Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry. 2004;65(7):975-981.
33. Papakostas GI, Shelton RC. Use of atypical antipsychotics for treatment-resistant major depressive disorder. Curr Psychiatry Rep. 2008;10(6):481-486.
34. Ravindran AV, Bradbury C, McKay M, da Silva TL. Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders. Expert Opin Pharmacother. 2007;8(11):1693-1710.
35. Müller-Siecheneder F, Müller MJ, Hillert A, Szegedi A, Wetzel H, Benkert O. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol. 1998;18(2):111-120.
36. Ostroff RB, Nelson JC. Risperisone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999;60(4): 256-259.
37. Viner MW, Chen Y, Bakshi I, Kamper P. Low dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation. J Clin Psychopharmacol. 2003;23(1):104-106.
38. McIntyre R, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord. 2003;5 Suppl 2:20-35.
39. Myers JE, Thase ME. Risperidone: review of its therapeutic utility in depression. Psychopharmacol Bull. 2001;35(4):109-129.
40. Nyberg S, Farde L, Halldin C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology. 1997;16(1):1-7.
41. Parker G, Malhi G. Are atypical antipsychotic drugs also atypical antidepressants? Aust N Z J Psychiatry. 2001;35(5):631-638.